Supplements slow disease progression during late stage of dry AMD, study suggests
A new analysis by researchers at the National Institutes of Health shows the benefit of taking AREDS2 formula in late AMD.
OGS Executive Director Lois Schoenbrun announces retirement
Schoenbrun will retire from the organization in December after coming out of retirement to serve as the interim executive director for OGS in 2022.
Bausch + Lomb acquires Trukera Medical, ophthalmic medical diagnostic company
According to the company, the tuck-in acquisition will help expand its surgical presence in the United States and contribute to its leading position in dry eye.
Stability is an important quality in toric lenses
The quality of options for patients has improved in recent years.
ASRS 2024: New data for Susvimo shows sustained efficacy in DME, DR
The 2-year Phase III data demonstrates Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema and diabetic retinopathy.
EyeCon 2024: Oluwatosin U. Smith, MD, talks about her love for research and education
From surgeon to mentor: Smith fuels her commitment to improving glaucoma care by training future ophthalmologists.
What happened in optometry this week: July 15 - July 19
Catch up on what happened in optometry during the week of July 15-July 19.
Optometry Giving Sight launches new year-round fundraising initiative
TEAM-OGS gives practices more fundraising opportunities to end preventable blindness and vision impairment globally throughout the year.
Dropless cataract surgery: Revolutionizing postoperative care for enhanced patient outcomes
Removing drops improves adherence and comfort for most patients.
NOA 2024: NOSA reflects on convention's networking and mentorship opportunities for students
Organization corresponding secretary Babirekere Bakama weighs in on her favorite learning opportunities at this year’s NOA Convention.
Keeping patient care personalized
An introduction to cerebral visual impairment.
Coupling of clinical trial recruitment and AI eases the burden of GA studies
Utilizing artificial intelligence may provide feasibility assessments, data-driven protocol design, and cost reduction opportunities.
NOA 2024: Eyerie Academics takes on student wellness and exam preparation
Cofounders Camille F. Cohen, OD, FAAO, and Janis James, OD, FAAO discuss what the organization has been up to at the National Optometric Association Convention.
Potential underlying corneal pathologies associated with alopecia areata
Study investigators conducted a case-control study to investigate the corneal topography parameters and biomechanics in patients with alopecia areata.
NOA 2024: Past president speaks on organization's continued initiatives
Sherrol A Reynolds, OD, speaks on event highlights from this year's NOA convention in Philadelphia, Pennsylvania.
NOA 2024: The dos and don'ts of prosthetic eye care
A. Philip Aitsebaomo, OD, PhD, informs eye care providers to get comfortable with handling prosthetics and stay educated to find the best fit for patients.
OKYO Pharma outlines plans for Phase 2 clinical trial of OK-101 in neuropathic corneal pain
The primary endpoint will be pain improvement as measured by visual analogue scale (VAS) compared to placebo.
What happened in optometry this week: July 8 - July 12
Catch up on what happened in optometry during the week of July 8-July 12.
NOA 2024: Myopia management starts with education
Educating parents of pediatric patients starts with getting staff on the same page.
Study finds potential link between semaglutide and risk of non-arteritic ischemic optic neuropathy
Prescriptions with semaglutide (Wegovy, Ozempic, Novo Nordisk) are FDA approved to treat obesity and type 2 diabetes, respectively.
